A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?

Summary

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shows potential as an antidepressant but may face challenges in becoming a mainstream treatment due to its unique characteristics and limited existing literature. Recruitment for diverse subjects in clinical trials is already difficult for psychedelics, which could further complicate studies involving 5-MeO-DMT. The article discusses the pros and cons of this compound and suggests recommendations for future trials.

Study at a glance

Abstract

As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean that its potential for success as a mainstream treatment option for depression is limited. There is very little existing literature around 5-MeO-DMT, and it is scarcely used even within the psychedelics community. This may mean that it is even more difficult to recruit a diverse range of subjects, which is already an issue for clinical trials involving other psychedelics. The aim of this article is to discuss the hypothetical pros and cons of 5-MeO-DMT as an antidepressant and to make recommendations for measures to be taken in any future clinical trials investigating 5-MeO-DMT.